And from the Ord Minnett Report -
"The key catalysts for the stock over the coming 12 months are likely to be related to trial results, with the next update expected in October 2012. The data will be in
relation to the 63 patient Phase IIb study (known as CAN-003), where preliminary efficacy data will be announced in conjunction with intracellular cytokine staining
(ICS) results, which will show whether CVac is producing the desired immune response. Good results would be a strong positive for the stock, in our view"
Things are looking quite spiffy I reckon
release interim cvac™ clinical data, page-3
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.015(5.36%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.0¢ | $833.4K | 2.824M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 388130 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 39940 | 3 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |